Effectiveness of Bivalent mRNA Booster Vaccine Against COVID-19 in Korea-Reference-Cited by-同舟云学术

Effectiveness of Bivalent mRNA Booster Vaccine Against COVID-19 in Korea

Published:2024 Issue:3 Volume:39 Page:
ISSN:1011-8934
Container-title:Journal of Korean Medical Science
language:en
Short-container-title:J Korean Med Sci

Author:

Yoon Jin Gu¹²^ORCID,Sohn Jang Wook³^ORCID,Choi Won Suk⁴^ORCID,Wie Seong-Heon⁵^ORCID,Lee Jacob⁶^ORCID,Lee Jin-Soo⁷^ORCID,Jeong Hye Won⁸^ORCID,Eom Joong Sik⁹^ORCID,Seong Hye¹²^ORCID,Nham Eliel¹²^ORCID,Choi Yu Jung¹²^ORCID,Noh Ji Yun¹²^ORCID,Song Joon Young¹²^ORCID,Cheong Hee Jin¹²^ORCID,Kim Woo Joo¹²^ORCID

Affiliation:

1. Division of Infectious Diseases, Department of Internal Medicine, Korea University Guro Hospital, Korea University College of Medicine, Seoul, Korea.

2. Vaccine Innovation Center-KU Medicine (VIC-K), Seoul, Korea.

3. Division of Infectious Diseases, Department of Internal Medicine, Korea University Anam Hospital, Korea University College of Medicine, Seoul, Korea.

4. Division of Infectious Diseases, Department of Internal Medicine, Korea University Ansan Hospital, Korea University College of Medicine, Ansan, Korea.

5. Division of Infectious Diseases, Department of Internal Medicine, St. Vincent’s Hospital, College of Medicine, The Catholic University of Korea, Suwon, Korea.

6. Division of Infectious Diseases, Department of Internal Medicine, Kangnam Sacred Heart Hospital, Hallym University College of Medicine, Seoul, Korea.

7. Division of Infectious Diseases, Department of Internal Medicine, Inha University School of Medicine, Incheon, Korea.

8. Department of Internal Medicine, Chungbuk National University College of Medicine, Cheongju, Korea.

9. Division of Infectious Diseases, Department of Internal Medicine, Gil Medical Center, Gachon University College of Medicine, Incheon, Korea.

Funder

SK Bioscience CO., Ltd

Publisher

XMLink

Subject

General Medicine

Link

https://jkms.org/pdf/10.3346/jkms.2024.39.e15

Reference21 articles.

1. Duration of Protection against Mild and Severe Disease by Covid-19 Vaccines

2. Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar

3. Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression

4. World Health Organization. Classification of Omicron (B.1.1.529): SARS-CoV-2 variant of concern. Updated 2021. Accessed August 30, 2023. https://www.who.int/news/item/26-11-2021-classification-of-omicron-(b.1.1.529)-sars-cov-2-variant-of-concern

5. Omicron variant showed lower neutralizing sensitivity than other SARS-CoV-2 variants to immune sera elicited by vaccines after boost